Search

everythinglearnresearchcommunity

for

Search:↓

The user has been using 1mg finasteride daily, minoxidil foam once or twice a day, and Nizoral shampoo 3-4 times weekly for 8 months, noticing some shedding but not much growth. Others suggest patience, microneedling, or additional treatments like dutasteride, PRP, or exosomes for better results.

The user has been using topical finasteride 0.1%, minoxidil 5%, red light therapy, a multi-peptide serum, and a weekly oil hair mask with various oils for hair loss treatment. They also use ketoconazole shampoo, condition their hair, and microneedle with a dermapen.

The user experienced hair regrowth after 4.5 months using oral finasteride and minoxidil, along with Nizoral shampoo, but faced brain fog and motivation issues, which improved after adjusting the finasteride dosage. Other users suggested checking hormone levels to address the brain fog, and congratulated the user on their progress.

The user experienced significant hair regrowth using topical Minoxidil and Finasteride, along with Saw Palmetto and volumizing shampoo. They are considering a hair transplant in the future if needed.

The user shared their 5-month progress using oral finasteride, topical minoxidil, and weekly dermarolling for hair loss. They expressed pride in their results, receiving positive feedback from others.

Aminexil/Kopexil may help reduce hair loss by addressing perifollicular fibrosis in androgenetic alopecia, but it lacks the extensive clinical backing of finasteride and minoxidil. Some users find it effective, but availability and cost are issues, especially in the US where it's not FDA-approved.

A 25-year-old male is experiencing advanced hair loss and is using topical and oral minoxidil, topical finasteride, and vitamin D3, but has not seen significant regrowth. He is considering switching treatments, including oral dutasteride, topical spironolactone, and possibly a scalp biopsy to better understand his condition.

Bimatoprost (Latisse) shows promise in treating scalp alopecia. Users discuss its potential alongside Minoxidil, finasteride, and RU58841.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

A user's 3.5 month progress using Minoxidil, finasteride, dermarolling, and keto shampoo for hair regrowth, with positive results being reported.